~~<i id='35C00EA95D'><strike id='35C00EA95D'><tt id='35C00EA95D'><pre id='35C00EA95D'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：focus 2025-10-03 01:08:47 Page View：34

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed
Next article： Novavax promises a turnaround & Lilly roils the obesity market

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Why hospitals are withdrawing from US News rankings

UniversityofPennsylvaniahospitalcomplexJonLovette/AlamyMercyPhiladelphiaHospitalwasplanningonshuttin

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

AustralianTimothyLyndsayShaddocksmilesashespeaksduringawelcomingceremonybyGrupoMarafterbeingrescuedf